The Evaluation of Anti-Mullerian Hormone (AMH) in Early Diagnosis of Polycystic Ovarian Syndrome (PCOS)

Abstract

Background: Polycystic ovarian syndrome (PCOS) is a common endocrine disorder that is accompanied by longterm complications. Anti-Mullerian hormone (AMH) is largely expressed by the granulosa cells of ovarian follicles (folliculogenesis) and is highest in the pre-antral and small antral stages (less than 4 mm in diameter) of development. The aim was to evaluate the role of anti-Mullerian hormone (AMH) in the early diagnosis of PCOS and find a cut-off level for PCOS. Methods: This cross-sectional study enrolled 60 women, aged 21–40 years who were referred to the outpatient department of Gynaecology and Obstetrics at the International Medical College Hospital, Gazipur, Shahid Tajuddin Ahmed Medical College, Gaziopur, Digital Hospital, Gazipur and Akber Clinic, Gazipur from January 2018 to December 2020. They were divided into two groups: 30 women with PCOS (based on the criteria of Rotterdam) as the case group, and 30 women as the control group. On days 2, 3, and 4 of the monthly menstrual cycle, transvaginal sonography was performed, and the serum level of AMH was measured in all participants. Results: The mean serum level of AMH in table II was significantly higher in the case group than in the control group. The mean value of AMH was 8.34 ng/ml, which indicates that the association between the transvaginal ultrasonogram (TVS) scan and the features of PCOS is statistically significant. Between the two groups, there were statistically significant variations in AMH levels and irregular menstrual patterns. But regarding age and body mass index, they were not significant. Conclusion: For the evaluation of PCOS in infertile women, AMH is a significant test.